1 / 31

Pharmacology of antidepressants and mood stabilisers

Pharmacology of antidepressants and mood stabilisers. Dr Caroline Stewart c.a.stewart@dundee.ac.uk. Learning Outcomes. List the main classes of antidepressant drug Describe the effects of antidepressant drugs on synaptic monoamine levels

diem
Download Presentation

Pharmacology of antidepressants and mood stabilisers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmacology of antidepressants and mood stabilisers Dr Caroline Stewart c.a.stewart@dundee.ac.uk

  2. Learning Outcomes • List the main classes of antidepressant drug • Describe the effects of antidepressant drugs on synaptic monoamine levels • Describe the principal adverse effects of each drug class • Define the term “mood stabiliser” and give examples

  3. Core Clinical Problems • Altered Mood • Anxiety • Arrested Intellectual Development • Behavioural Problems in Adults • Deliberate Self Harm • Eating Disorders • Medically Unexplained Symptoms • Memory Problems • Misusing Drugs or Alcohol • Psychological Responses to Trauma • Psychosis

  4. CNS pharmacology • Synaptic transmission (chemical) • Formation, storage, release, action, inactivation of neurotransmitters • Variety and distribution of neurotransmitters and receptor subtypes • Access of drugs to the brain (BBB) • see “Neuropharmacology introduction” on Blackboard

  5. Antidepressant drugs • Monoamine oxidase inhibitors • Monoamine reuptake inhibitors • Tricyclics & related • selective serotonin reuptake inhibitors • other non-selective reuptake inhibitors • Atypical drugs (post-synaptic receptor effects)

  6. OH CH– CH2 –NH2 HO HO CH2 – CH2 –NH2 HO H — N The monoamine hypothesis • Depression results from a functional deficit of monoamine transmitters (Schildkraut 1965) particularly: noradrenaline and serotonin (5-HT) • Drugs that deplete stores of monoamines (e.g. reserpine) can induce low mood • CSF from depressed patients have reduced levels of monoamines or metabolites • Most drugs that treat depression act to increase monoaminergic transmission

  7. Noradrenaline pathways in human brain Cingulate Gyrus Frontal Cortex Thalamus Hippocampus • Locus coeruleus • LC → forebrain, brain stem, spinal cord • control of arousal, sleep-wake cycle, anxiety Locus coeruleus A Amygdala Lateral tegmental area • Brain stem • anterior → limbic structures; posterior → brain stem, spinal cord • role unclear

  8. The noradrenergic synapse Tyrosine hydroxylase Reserpine L-AA decarboxylase X tyr VMAT metabolites DOPA MAOA dopamine 2 DA ß-hydroxylase noradrenaline NET PLC 1 AC 2  Gq Gs Gi COMT (-) (+) ion channels cAMP IP3, DAG, Ca2+ cellular responses

  9. Serotonin pathways in human brain • arousal • sleep • stress • attention • sexual behaviour • mood regulation (e.g. aggression) • processing of sensory information in cerebral cortex Cingulate Gyrus Frontal Cortex Thalamus Hippocampus Rostral Amygdala Caudal Raphe

  10. The serotonergic synapse Reserpine tryptophan hydroxylase X tryp metabolites VMAT L-AA decarboxylase MAOB 5-OHTryp 5HT1D serotonin SERT MAO AC PLC 5HT1A Gi Gs 5HT2C/D Gq 5HT4,5,6 (-) (+) 5HT3 ion channels cAMP IP3, DAG, Ca2+ cellular responses

  11. Monoamine oxidase inhibitors • MAOA (expressed in NA neurones) – selective for NA, 5-HT • MAOB(expressed in 5-HT neurones) – selective for -phenylethylamine, benzylamine • Both – DA, tyramine, tryptamine • MAOA inhibition – clorgyline, tranylcypromine, phenelzine, isocarboxazid • MAOB inhibition – selegiline, tranylcypromine, phenelzine, isocarboxazid • Meclobemide is reversible MAOA inhibitor

  12. Monoamine oxidase inhibitors: site of action metabolites MAO inhibitor precursor MAO X neurotransmitter PLC AC Gq Gs Gi (-) (+) ion channels cAMP IP3, DAG, Ca2+ cellular responses

  13. Monoamine oxidase inhibitors: adverse effects • “Cheese reaction” caused by inhibition of MAO-A in gut (& liver). Irreversible inhibitors prevent breakdown of dietary tyramine – requires dietary restriction • Drug preparations also containing amines should be avoided (e.g. pseudoephedrine) • Potentiates the effects of tricyclic antidepressants e.g. on hypertension • Potentiates effects of depressant drugs (e.g. barbiturates, morphine, ethanol) by decreasing their metabolism

  14. Tricyclic & related antidepressants LIVER imipramine desmethylimipramine LIVER amitriptyline nortriptyline clomipramine mianserin trazodone

  15. Tricyclic & related drugs: site of action metabolites precursor MAO neurotransmitter X Reuptake inhibitors PLC AC Gq Gs Gi (-) (+) ion channels cAMP IP3, DAG, Ca2+ cellular responses

  16. Tricyclic antidepressants: adverse effects • Improvement over MAOIs: • No dietary control required • Less severe drug interactions • Adverse effects: • muscarinic blockade • sedation • cardiac arrhythmias • postural hypotension

  17. Selective serotonin reuptake inhibitors citalopram escitalopram fluoxetine fluvoxamine maleate paroxetine sertraline

  18. SSRIs: site of action tryp metabolites MAO 5-HTryp 5HT1D serotonin X SERT SSRIs AC PLC 5HT1A Gi Gs 5HT2C/D Gq 5HT4,5,6 (-) (+) 5HT3 ion channels cAMP IP3, DAG, Ca2+ cellular responses

  19. SSRIs: adverse effects • Improvements over MAOIs & tricyclics • Non sedative • Less cardiac effects • Adverse effects: • Nausea/diarrhoea • Insomnia • sexual dysfunction • suicidal behaviour

  20. Other monoamine reuptake inhibitors • Dual reuptake inhibitors e.g venlafaxine • Mode of action: Block the reuptake of monoamines (noradrenaline and/or 5-HT) into presynaptic terminals. • Side effects: Lack major receptor-blocking actions so fewer side effects

  21. Selective NA reuptake inhibitors? • Atomoxetine inhibits NET and also DAT • Reboxetine selective inhibitor of NET which was approved for major depression in 1997 • Systematic review and meta-analysis (BMJ 341: c4737–c4737. doi:10.1136/bmj.c4737) has now determined • no overall significant difference compared to control • inferior response compared to SSRIs • greater harm than placebo or SSRIs for adverse events

  22. Selectivity of uptake inhibitors

  23. Atypical antidepressant drugs • Agomelatine: a melatonin receptor agonist and a selective serotonin-receptor antagonist • Mirtazapine: mixed receptor effects (blocks 2, 5-HT2)

  24. Efficacy of current antidepressants • Most classes of drug have a similar clinical efficacy (40-70%) • Side effect profiles differ • Most have delayed onset of action (several weeks) • How do they actually work? • Long-term adaptation in receptor density/function? • Alterations in corticosteroid receptors/HPA function?

  25. Antidepressant drugs: clinical uses • Moderate to severe depression • Dysthymia • Generalised anxiety disorder • Panic disorder, OCD, PTSD • Premenstrual dysphoric disorder • Bulimia nervosa • Neuropathic pain

  26. Acute treatment of symptoms: antipsychotics for episodes of mania antidepressants for episodes of depression Bipolar affective disorder treatment Stabilise mood and prevent recurrence (prophylaxis): • lithium salts • anticonvulsants

  27. Lithium therapy • Discovered accidentally: Normally given as lithium carbonate • Mode of action: • block of phosphatidylinositol pathway (second messenger system)? • inhibition of glycogen synthase kinase-?

  28. Inositol depletion hypothesis PLC AC Gq Gs Gi (-) (+) ion channels cAMP IP3, DAG, Ca2+ cellular responses DAG PLC Gq IP3 PIP2 I IP Glucose IMPase Li+

  29. Side effects of lithium therapy • nausea, vomiting, anorexia, diarrhoea, tremor, polydipsia, polyuria • lithium toxicity (drowsiness, ataxia and confusion) • Blood levels must be monitored

  30. Anticonvulsants as mood stabilisers • Drugs like carbamazepine and valproic acid are now being for prophylaxis in bipolar disorder • Mode of action: very unclear, perhaps block overactive pathways (kindling model of bipolar disorder) • Side effects: • carbamazepine: drowsiness, ataxia, cardiovascular effects, induces liver enzymes • valproate: liver failure, teratogenicity (neural tube defects)

  31. The End

More Related